Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.34
-0.17 (-0.67%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Nurix Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Buy" and an average price target of $34.5. The average 1-year stock price forecast is 36.15% higher than the current stock price, while the lowest is $25 (-1.34%) and the highest is $45 (+77.58%).
Price Target: $34.5 (+36.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 10 | 9 | 8 | 8 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 15 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $34 → $36 | Buy | Reiterates | $34 → $36 | +42.07% | Oct 16, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $38 | Buy | Maintains | $38 | +49.96% | Oct 15, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $28 → $32 | Buy | Reiterates | $28 → $32 | +26.28% | Oct 13, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $34 → $33 | Buy | Reiterates | $34 → $33 | +30.23% | Oct 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $35 | Buy | Reiterates | $35 | +38.12% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
744.85M
from 83.98M
Increased by 786.93%
Revenue Next Year
123.22M
from 744.85M
Decreased by -83.46%
EPS This Year
3.05
from -3.05
EPS Next Year
-1.60
from 3.05
EPS and Forward PE are based on non-GAAP adjusted numbers.